A practical review on carfilzomib in multiple myeloma.
Muchtar E et al. Eur J Haematol. 2016 Feb 19. doi: 10.1111/ejh.12749. [Epub ahead of print].

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going
Thanendrarajan S et al. Immunotherapy. 2016 Feb 17. [Epub ahead of print].

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Shah JJ et al. Blood Cancer J. 2016 Feb 12;6:e396. doi: 10.1038/bcj.2016.4.

Targeting Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
Lum LG et al. Biol Blood Marrow Transplant. 2016 Jan 28. pii: S1083-8791(16)00090-2. doi: 10.1016/j.bbmt.2015.12.030. [Epub ahead of print].

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma.
Gupta N et al. J Clin Pharmacol. 2016 Feb 13. doi: 10.1002/jcph.719. [Epub ahead of print].